US sign-up averts major EU crisis, but India, China actives still problematic
This article was originally published in Scrip
Executive Summary
New EU rules on importing Active Pharmaceutical Ingredients coming into force on 2 July may bring problems for European manufacturers and patients, industry sources are still warning. But the situation for companies could be better than feared because the major sources of APIs such as the US, India and China, have made it clear that they will, after all, comply with the EU regulation.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.